You may view clinical & university studies below, specifically for the use of CHEATmeals™ and its ingredients. All tests are done via a double blind, placebo-controlled trials for complete accuracy and effectiveness.
If you'd like to view additional research materials, clinical studies and reference data, please view our "Ingredients" page.
Clinical & University Studies
PROVE CHEATmeals® Works
Below you'll find a variety of randomized university clinical tests proving
that the ingredients found in CHEATmeals™ decreases body fat and weight,
with NO change in diet or additional exercise.
Study #1:
University of Scranton, PA. (30 days) |
Graphical % |
Weight Loss (%) |
| Use of CHEATmeals™ |
 |
3.9% BW
10.45% BFM |
| Placebo |
 |
gain 0.89% |
Study #2:
12-week randomized, placebo-controlled, double-blind |
Graphical % |
Weight Loss (lbs) |
| Use of CHEATmeals™ |
|
10.7 |
| Placebo |
 |
2.04 |
Study #3:
8-week study, 49 participants |
Graphical % |
Weight Loss (lbs) |
| Use of CHEATmeals™ |
|
6.93 |
| Placebo |
 |
gain 1.33 |
|
 |
|
| |
| 1. |
Bo-Linn, G.W., et al., Starch blockers--their effect on calorie absorption from a high-starch meal. N Engl J Med, 1982. 307(23): p. 1413-6. |
| 2. |
Layer, P., G.L. Carlson, and E.P. DiMagno, Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans. Gastroenterology, 1985. 88(6): p. 1895-902. |
| 3. |
Investigation of the efficacy of Phase 2™ . Joe A. Vinson, Ph.D. Department of Chemistry University of Scranton |
| 4. |
Summary of clinical study evaluating effectiveness of Phaseolamin® Dr. R. Ballerini, Managing Director of Pharmeceutical Development and Service srl. Milano, Italy |
| 5. |
In vivo effectiveness of a starch absorption blocker in a double-blind placebo-controlled study with normal college-age subjects. Joe A. Vinson, PhD and Donna M. Shuta, BS Department of Chemistry University of Scranton Scranton, PA 18510 |
| 6. |
In vivo effectiveness of a starch absorption blocker in a double-blind placebo-controlled study with normal subjects. Joe A. Vinson, PhD, Donna M. Shuta, BS and Hassan Al Kharrat, MS Department of Chemistry University of Scranton Scranton, PA 18510 |
| 7. |
Tappenden KA, et al. FASEB J 2001; 15(4):A301. |
| 8. |
Thom E. J Int Med Res 2000; 28:229-33. |
|
|
|
| |
| • |
Michihiro, S. et al, "Hypocholestererolemic action of Chitosans with different viscosity in rats," Laboratory Nutrition, Saga University 1988 |
| • |
Nauss J L, et al, "The Binding of Micellar lipids to Chitosan," Lipids 18 (10). 1983. 714-719 Chitosan absorbs 4-6 times its own weight in fat |
| • |
Kanauchi, K. et al. "Mechanism for the inhibition of fat digestion by Chitosan," Bosci Biotechnol Biochem, 1995 May: 59 (5): 786-90 |
| • |
Deuchi, O. et al. "Decreasing effect of Chitosan on the apparent fat digestibility by rats fed on high fat diet," Bioscience Biotechnology and Biochemistry, 1994 |
| • |
Chobot, V. "Physiotherapeutic aspects of diseases of the circulatory system," Ceska a Slovenska Farmacie, Aug 44: 190-5, 1995 |
| • |
Chandy, T. Sharma, C.P. "Chitosan - as a biomaterial biosurface technology division," Sree Chita Triunal Institute for Medical Sciences and Technology, Poojandrum, India. 1990 |
| • |
Vahouny G.V. et al. American Journal of Clinical Nutrition, Aug 1983, 38 (2) p 278-84, ISSN 2-9165, Journal Code: 3EY |
| • |
LeHoux, J.G. et al. "Some effects of Chitosan on liver function of rats," Endocrinology, 1993, March l078-84 |
| • |
Zochina, Z.M. et al. "Inhibition of Chitosan of infection of t-series bacteriophages in the escherichia coli," Mikrobiologia, 1995 March/April: 64 (2) 211-5 |
| • |
Sugana, M Fujikawa, T. "Hiratsuji, Y. Nakashima, K. Fukunda, N. and Hasegawa, Y. "A novel use of Chitosan as a hypocholesterolemic agent in rats," American Journal of Cain. Nutrition, April 1980: pages 787-793 |
| • |
Birketvedt G.S. Clinical Report, Dovre Medical Center, Fjellhammer, Norway, May 1991 |
|
Order 24 Hours A Day/7 Days A Week -- Global, World-Wide Shipping
|
|
